According to research approximately 18.6 million Americans had symptoms of GERD (gastrointestinal reflux disease) in 2010. About 10%-15% percent of GERD patients will develop Barrett’s Esophagus (BE). Less than 1% of Barrett’s patients will develop esophageal cancer. A small percentage but a substantial number of people diagnosed diagnosed annually with an aggressive cancer.
I’ve learned that most people will make a reasonable effort to reduce their risk of cancer if:
GERD or Barrett’s Esophagus is your incentive to take steps to reduce your risk of esophageal cancer. Curcumin, one of many non-toxic therapies shown to reduce the risk of esophageal cancer, is inexpensive and proven.
Do you suffer from GERD? BE? EC? Are you interested on safe, non-toxic therapies to reduce your risk of esophageal cancer?
I am a long-term cancer survivor and cancer coach. I take Life Extension Super Bio Curcumin daily. This brand of curcumin is more bioavailable than others and has been tested and approved by consumerlab.com.
Scroll down the page, post a question or comment and I will reply to you ASAP.
“GERD, also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications. Symptoms include the taste of acid in the back of the mouth, heartburn, bad breath, chest pain, vomiting, breathing problems, and wearing away of the teeth. Complications include esophagitis, esophageal strictures, and Barrett’s esophagus.“
“We examined the molecular mechanism of curcumin in a preventive and therapeutic model of indomethacin-induced gastric ulceration with regard to angiogenic processes.
Disrupted blood vessels, reduced collagen matrices, and significant (60%) injury to mucosal cells were observed during ulceration. In addition, ulcerated tissues exhibited decreased matrix metalloproteinase (MMP)-2 and vascular endothelial growth factor (VEGF) expression in blood vessels. Interestingly, curcumin blocked ulceration by induction of collagenization and angiogenesis in gastric tissues via upregulation of MMP-2, membrane type (MT) 1-MMP, VEGF, and transforming growth factor (TGF)-β at protein and messenger ribonucleic acid (mRNA) levels. To examine the angiogenic properties of curcumin, we employed a chorioallantoic membrane model and Matrigel assay. During healing, curcumin promoted collagenization and angiogenesis as well as enhanced MMP-2 activity via positive MT1-MMP regulation and negative tissue inhibitor of metalloproteinase-2 regulation.
Our study demonstrates that curcumin-mediated healing is associated with increased MMP-2, TGF-β, and VEGF expression and that it plays a pivotal role as an angiogenic modulator by stimulating vascular sprout formation and collagen fiber restoration in ulcerated tissues.
We conclude that curcumin remodels gastric tissues by restoring the collagen architecture and accelerating angiogenesis.